Related Experiment Videos
Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their
1Center for Vitamin and Cancer Research, Department of Radiology, University of Colorado Health Sciences Center, Denver 80262-0278, USA. kedar.prasad@uchsc.edu
Integrative Cancer Therapies
|November 4, 2004
Summary
Dietary antioxidants may enhance cancer treatment efficacy and reduce side effects. Nutritional protocols can also improve quality of life for unresponsive patients and lower recurrence risk in survivors.
Area of Science:
- Oncology
- Nutritional Science
Background:
- Cancer therapy faces challenges with plateauing efficacy for solid tumors and limited options for unresponsive patients.
- Survivors of cancer are at risk for recurrence or secondary malignancies, with no current strategies to mitigate this risk.
Purpose of the Study:
- To propose active and maintenance nutritional protocols using dietary antioxidants as adjuncts to conventional cancer therapies.
- To explore the potential of these protocols to improve treatment efficacy, reduce toxicity, enhance quality of life, and lower cancer recurrence risk.
Main Methods:
- Review of experimental data and limited human studies on the use of specific dietary antioxidants (vitamin C, alpha-tocopheryl succinate, natural beta-carotene).
- Proposal of distinct nutritional protocols for active treatment, for patients unresponsive to therapy, and for long-term maintenance.
Main Results:
- Adjunctive nutritional protocols may improve tumor response and decrease toxicity during radiation therapy, chemotherapy, or experimental therapies.
- Nutritional interventions could potentially improve quality of life and survival time for patients unresponsive to standard treatments.
Conclusions:
- Dietary antioxidant protocols show promise for improving oncologic outcomes and reducing treatment-related toxicity.
- Maintenance nutritional protocols, combined with lifestyle modifications, may reduce the risk of cancer recurrence and secondary cancers in survivors.